A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients

Kidney International

Volumn 54, Issue 6, 1998, Pages 2064-2080

  Demant, Thomas ^a   Mathes, Christoph ^b   Gütlich, Katja ^b   Bedynek, Andrea ^b   Steinhauer, Hjalmar B ^b   Bosch, Thomas ^b   Packard, Christopher J ^b   Warwick, Graham L ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Albumin; Apolipoprotein B; Hyperlipidemia; Kinetic analysis; Nephrotic syndrome; Stable isotopes

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISOTOPE LABELING; LIPOPROTEIN METABOLISM; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS;

EID: 0031756889     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00204.x     Document Type: Article

References (50)

1. BAXTER JH, GOODMAN HC, HAVEL RJ: Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest 39:455-465, 1960
2. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993
3. WARWICK GL, PACKARD CJ: Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: Clinical implications. Miner Electrolyte Metab 19:115-126, 1993
4. CURRY RC, ROBERTS WC: Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 63:183-192, 1977
5. ORDONEZ JD, HIATT RA, KJLLEBREW EJ, FIREMAN BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
6. JOVEN J, VILLABONA C, VILELLA E, MASANA L, ALBERTI R, VALLES M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584, 1990
7. APPEL GB, BLUM CB, CHIEN S, KUNIS CL, APPEL AS: The hyperlipidemia of the nephrotic syndrome: Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 312:1544-1548, 1985
8. WARWICK GL, PACKARD CJ, DEMANT T, BEDFORD D, BOULTON-JONES JM, SHEPHERD J: Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40:129-138, 1991
9. WARWICK GL, CASLAKE MJ, BOULTON-JONES JM, DAGEN M, PACKARD CJ, SHEPHERD J: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 39:187-192, 1990
10. VEGA GL, TOTO RD, GRUNDY SM: Metabolism of low density lipoprotein in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 47:579-586, 1995
11. VEGA GL, GRUNDY SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160-1168, 1988
12. AGUILAR-SALINAS CA, BARRETT PHR, KELBER J, DELMEZ J, SCHONFELD G: Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J Lipid Res 36:188-199, 1995
13. GARBER DW, GOTTLIEB BA, MARSH JB, SPARKS CE: Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74:1375-1383, 1984
14. MARSH JB, DRABKIN DL: Experimental reconstruction of metabolic pattern of lipid nephrosis: Key role of hepatic protein synthesis in hyperlipidemia. Metabolism 9:946-955, 1960
15. GOLPER TA, FEINGOLD KR, FULFORD MH, SIPERSTEIN MD: The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat. J Lipid Res 27:1044-1051, 1986
16. STAPRANS I, FELTS JM, COUSER WG: Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism 36:496-501, 1987
17. YOSHINO G, HIRANO T, NAGATA K, MAEDA E, NAKA Y, MURATA Y, KAZUMI T, KASUGA M: Hypertriglyceridemia in nephrotic rats is due to a clearance defect of plasma triglyceride: Overproduction of triglyceride-rich lipoprotein is not an obligatory factor. J Lipid Res 34:875-884, 1993
18. YAMAUCHI A, FUKUHARA Y, YAMAMOTO S, YANO F, TAKENAKA M, IMAI E, NOGUCHI T, TANAKA T, KAMADA T, UEDA N: Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 263:C397-C404, 1992
19. CIANFLONE K, VU H, ZHANG Z, SNIDERMAN AD: Effects of albumin on lipid synthesis, apo B-100 secretion, and LDL catabolism in HepG2 cells. Atherosclerosis 107:125-135, 1994
20. PULLINGER CR, NORTH JD, TENG BB, RIFICI VA, DE BRITO AER, SCOTT J: The apolipoprotein B gene is constitutively expressed in HepG2 cells: Regulation of secretion by oleic acid, albumin and insulin and measurement of the mRNA half-life. J Lipid Res 30:1065-1077, 1989
21. MARSH JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25:1619-1622, 1984
22. 13C leucine. Kidney Int 41:132-138, 1992
23. KAYSEN GA, GAMBERTOGLIO J, FELTS J, HUTCHISON FN: Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 31:1368-1376, 1987
24. DEMANT T, PACKARD CJ, DEMMELMAIR H, STEWART P, BEDYNEK A, SEIDEL D, SHEPHERD J: Sensitive methods to study human apolipoprotein B metabolism using stable isotope labelled amino acids. Am J Physiol 270:E1022-E1036, 1996
25. PARHOFER KG, BARRETT PHR, BIER D, SCHONFELD G: Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 32:1311-1323, 1991
26. DEMANT T, MATHES C, BEDYNEK A, BOSCH T, SEIDEL D: Simultanous measurement of apolipoprotein B and albumin metabolism using gas chromatography-mass spectrometry and multicompartmental data analysis. Eur J Clin Invest 33:A26, 1995
27. SEMAN LJ, JENNER JL, MCNAMARA JR, SCHAEFER EJ: Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem 40:400-403, 1994
28. TRAVIS J, PANNELL R: Selective removal of albumin from plasma, Clin Chim Acta 49:49-52, 1973
29. PETERS T: Serum albumin. Adv Prot Chem 37:161-245, 1985
30. ADAMS RF: Determination of amino acid profiles in biological samples by gas chromatography. J Chromatogr 95:189-212, 1974
31. COBELLI C, TOFFOLO G, FOSTER D: Tracer-to-tracee ratio for analysis of stable isotope tracer data: Link with radioactive kinetic formalism. Am J Physiol 262:E968-E975, 1992
32. FOSTER DM, BARRETT PHR, TOFFOLO G, BELTZ WF, COBELLI C: Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 34:2193-2205, 1993
33. REEDS PJ, HACHEY DL, PATTERSON BW, MOTIL KJ, KLEIN PD: VLDL apolipoprotein B-100, a potential indicator of the isotopic labeling of the hepatic protein synthetic precursor pool in humans: Studies with multiple stable isotopically labeled amino acids. J Nutr 122:457-466, 1991
34. DEMANT T, GAW A, WATTS GF, DURRINGTON P, BUCKLEY B, IMRIE CW, WILSON C, PACKARD CJ, SHEPHERD J: Metabolism of apo B-100 containing lipoproteins in familial hyperchylomicronemia. J Lipid Res 34:147-156, 1993
35. DEMANT T, CARLSON LA, HOLMQUIST L, KARPE F, NILSSON-EHLE P, SHEPHERD J: Lipoprotein metabolism in hepatic lipase deficiency: Studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 29:1603-1611, 1988
36. KASHYAP ML, SRIVASTAVA LS, HYND BA, BRADY D, PERISUTTI G, GLUECK CJ, GARTSIDE PS: Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29-40, 1980
37. BREIER CH, LISCH HJ, BRAUNSTEINER H: Lipoproteine, Apolipoproteine, Lipoproteinlipase, hepatische Triglyceridlipase und Lecithin-Cholesterin-Acyl-Transferase bei Patienten mit nephrotischem Syndrom. Schweiz Med Wschr 113:909-913, 1983
38. CHAN MK, VARGHESE Z, PERSAUD JW, MOORHEAD JF: Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aust NZ J Med 14:841-847, 1984
39. CALANDRA S, GOTTARDI E, TARUGI P: Plasma post-heparin lipolytic activity in rats with nephrotic syndrome. Hormone Metab Res 15:361, 1983
40. FURUKAWA S, HIRANO T, MAMO JCL, NAGANO S, TAKAHASHI T: Catabolic defect of triglyceride is associated with abnormal very low density lipoprotein in experimental nephrosis. Metabolism 39:101-107, 1990
41. SHEPHERD J, CASLAKE M, LORIMER AR, VALLANCE BD, PACKARD CJ: Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 5:162-168, 1985
42. GOLDBERG ACK, ELIASCHEWITZ FG, QUINTAO ECR: Origin of hypercholesterolemia in chronic experimental nephrotic syndrome. Kidney Int 12:23-27, 1977
43. MCKENZIE IFC, NESTEL P: Studies on the turnover of trigylyceride and esterified cholesterol in subjects with the nephrotic syndrome. J Clin Invest 47:1685-1695, 1968
44. PEASE RJ, LEIPER JM: Regulation of hepatic apolipoprotein B-containing lipoprotein secretion. Curr Opin Lipidol 7:132-138, 1996
45. TASKINEN MR, PACKARD CJ, SHEPHERD J: Effect of insulin therapy on the metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017-1027, 1990
46. THOMSON GR, NAOUMOVA RP, WATTS GF: Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 37:439-447, 1996
47. KATZ J, BONORRIS G, OKUYAMA S, SELLERS AL: Albumin synthesis in perfused liver of normal and nephrotic rats. Am J Physiol 212:1255-1260, 1967
48. JENSEN H, ROSSING N, ANDERSEN SB, JARNUM S: Albumin metabolism in the nephrotic syndrome in adults. Clin Sci 33:445-457, 1967
49. BAXTER JH, GOODMAN HC, ALLEN JC: Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 40:490-497, 1961
50. HIRANO T, FURUKAWA S, KUROKAWA M, EBARA T, DIXON JL, NAGANO S: Intracellualr apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. Kidney Int 47:412-431, 1995